Marion Laboratories Inc's stock rosesharply today after the company presented a bullish earningsscenario at a meeting for pharmaceutical analysts Monday,traders and analysts said.    The company said it expects earnings for fiscal 1987,ending June 30, to rise more than 75 pct over a year ago.    That pronouncement encouraged analyst David Crossen ofSanford C. Bernstein and Co to raise his earnings estimates forthe company to 1.28 dlrs a share in 1987, compared to hisprevious estimate of 1.20 dlrs a share. Last year the companyearned 70 cts a share.    Marion's stock gained 3-1/4 to 75-1/2.    At the meeting of pharmaceutical analysts, Marion'spresident Fred Lyons Jr. said Wall Street eanrings estimates of1.10-1.15 dlrs a share for fiscal 1987 "are expected to causeeven the aggressive side of this range to be 10 to 15 cts low."    Lyons said the strong performance in the second half ofthis year will result from the fourth quarter introduction of90 mg and 120 mg Cardizem tablets. Analyst Crossen said thatCardizem, which treats angina, is also expected to be approvedfor the treatment of hypertension by the end of the year.    Crossen said "because Marion is still just a small company,the growth of Cardizem is having a big impact on the bottomline." He raised fiscal 1988 earnings estimates to 2.15 dlrs ashare from his previous estimate of 2.05 dlrs a share.    "The company has a broad new product pipeline in theindustry and as far as I am concerned, it is the mostinnovative company in the business," he said.    For the five years through 1991, Crossen expects Marion tohave a growth rate of 55 pct. Reuter&#3;